Hypoglycemia Unawareness in Older Compared With Middle-Aged Patients With Type 2 Diabetes by Bremer, Jan P. et al.
Hypoglycemia Unawareness in Older
Compared With Middle-Aged Patients With
Type 2 Diabetes
JAN P. BREMER, MD
1
KAMILA JAUCH-CHARA, MD
2
MANFRED HALLSCHMID, PHD
3
SEBASTIAN SCHMID, MD
1
BERND SCHULTES, MD
1,4
OBJECTIVE — Older patients with type 2 diabetes are at a particularly high risk for severe
hypoglycemicepisodes,andexperimentalstudiesinhealthysubjectshintatareducedawareness
of hypoglycemia in aged humans. However, subjective responses to hypoglycemia have rarely
been assessed in older type 2 diabetic patients.
RESEARCH DESIGN AND METHODS — We tested hormonal, subjective, and cogni-
tive responses (reaction time) to 30-min steady-state hypoglycemia at a level of 2.8 mmol/l in 13
older (65 years) and 13 middle-aged (39–64 years) type 2 diabetic patients.
RESULTS — Hormonal counterregulatory responses to hypoglycemia did not differ between
older and middle-aged patients. In contrast, middle-aged patients showed a pronounced in-
crease in autonomic and neuroglycopenic symptom scores at the end of the hypoglycemic
plateau that was not observed in older patients (both P  0.01). Also, seven middle-aged
patients,butonlyoneolderparticipant,correctlyestimatedtheirbloodglucoseconcentrationto
be 3.3 mmol/l during hypoglycemia (P  0.011). A profound prolongation of reaction times
induced by hypoglycemia in both groups persisted even after 30 min of subsequent euglycemia.
CONCLUSIONS — Our data indicate marked subjective unawareness of hypoglycemia in
oldertype2diabeticpatientsthatdoesnotdependonalteredneuroendocrinecounterregulation
and may contribute to the increased probability of severe hypoglycemia frequently reported in
these patients. The joint occurrence of hypoglycemia unawareness and deteriorated cognitive
function is a critical factor to be carefully considered in the treatment of older patients.
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H
ypoglycemiaisthelimitingfactorin
the glycemic management of diabe-
tes (1). For a long time hypoglyce-
miawasassumedamajorproblemonlyin
patients suffering from type 1 diabetes
(2); however, there is increasing evidence
that hypoglycemic episodes are a critical
factor also in type 2 diabetes (3,4). Older
subjects aged 65 years, who represent
the majority of type 2 diabetic patients,
appear at a particularly high risk of ex-
periencing severe hypoglycemia (3,4).
Previous studies (5–7) have shown
weakened perception of hypoglycemia-
related symptoms in healthy older (i.e.,
nondiabetic older subjects, aged 65–80
years)ascomparedwithyoungersubjects
(aged 24–49 years). Of note, in aged hu-
mans, the perception of hypoglycemic
symptoms was found to simultaneously
occur with the impairment of cognitive
functions during a stepwise reduction of
blood glucose levels (7), contrasting the
well-known hierarchical succession of
central nervous responses to hypoglyce-
mia in younger healthy adults who nor-
mally perceive hypoglycemic symptoms
at higher glucose levels than cognitive
dysfunction (4). The concurrence of gly-
cemic thresholds for the onset of symp-
tomsandofcognitivedysfunctionmaybe
expected to increase the risk for severe
hypoglycemic episodes since it likely pre-
vents behavioral counteractions (e.g., the
intake of carbohydrates) (3).
To date only one study (8) has as-
sessed subjective responses to standard-
ized hypoglycemia in older type 2
diabetic patients (aged 72  1 years), re-
vealing an impairment in the perception
ofhypoglycemicsymptomsthatwascom-
parable to that of age-matched healthy
control subjects. Although this ﬁnding
points to a decrease in hypoglycemia
awareness that develops in the course of
aging also in type 2 diabetic patients, this
assumption has not yet been experimen-
tally elucidated. Moreover, in the previ-
ous studies in healthy subjects (5–7), the
agegapbetweenexperimentalgroupswas
rather large, raising the question as to the
perception of hypoglycemia in middle-
aged subjects. On this background, we
examined whether older (aged 65
years) as compared with middle-aged
(aged 39–64 years) type 2 diabetic pa-
tientsdifferintheirsubjectiveresponseto
hypoglycemia and how hypoglycemia
awareness in these age-groups relates to
hormonal and cognitive effects of
hypoglycemia.
RESEARCH DESIGN AND
METHODS— We examined 13 older
(aged 65 years) and 13 middle-aged
(aged 39–64 years) type 2 diabetic pa-
tients matched for BMI, A1C, and sex in a
single-step hypoglycemic clamp experi-
ment (see Table 1 for subjects’ character-
istics). While type 2 diabetes therapy was
comparable between groups, the older
patients, as expected, displayed a longer
disease duration than the middle-aged
subjects. However, none of the patients
displayed any clinical evidence of diabe-
tes complications, such as neuropathy,
overt nephropathy (macroproteinuria),
coronary heart disease, or a history of
stroke. Also, none of the patients had ex-
perienced a severe hypoglycemic episode
that required help from another person
during the last year before the experi-
ments. All patients gave written informed
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the local ethics committee.
On the day of the experiment, pa-
tients reported to the medical research
unitat0730h.Theexperimenttookplace
in a sound-attenuated room with patients
sitting on a bed with their trunk in an
almost upright position (60°) and their
legs in a horizontal position. For blood
sampling, a cannula was inserted into a
veinonthebackofahandthatwasplaced
in a heated box (50–55°C) to obtain arte-
rialized venous blood. A second cannula
was inserted into an antecubital vein of
thecontralateralarm.Bothcannulaewere
connectedtolong,thintubesthatenabled
blood sampling and adjustment of the
rate of dextrose infusion from an adjacent
room without being noticed by the sub-
ject. After a 30-min baseline period start-
ing at 0800 h, a bolus of 0.08 IU human
insulin per kg body wt (Insuman Rapid;
Aventis, Strasbourg, France) was admin-
isteredover4min.Thereafter,insulinwas
infusedataconstantrateof2.5mUperkg
body wt per min. Blood glucose concen-
tration was measured every 5 min and
wasallowedtofalltoalevelof2.8mmol/l,
where it was maintained for the next 30
min by appropriately adjusted infusion of
20% dextrose solution. Immediately after
the 30-min hypoglycemic plateau, the in-
sulininfusionwasstoppedandbloodglu-
cose levels were normalized by increasing
the rate of dextrose infusion. Blood sam-
ples were drawn once during the baseline
period (i.e., before the clamp) and every
15 min during the 30-min hypoglycemic
plateau.
During the baseline period, at the be-
ginning and end of the 30-min hypogly-
cemic plateau and 30 min thereafter,
patientsﬁlledinasemiquantitativesymp-
tom questionnaire, rating 11 symptoms
(i.e., dizziness, tingling, blurred vision,
difﬁculty to concentrate, faintness, anxi-
ety, palpitation, hunger, sweating, irrita-
bility, and tremor) from 0 (not at all) to 9
(severe). In accordance with previous in-
vestigators (9), the ﬁrst ﬁve symptoms
were considered neuroglycopenic symp-
toms and the latter six were considered
autonomic symptoms. Immediately after
ﬁllinginthequestionnaires,patientswere
asked to estimate their current blood glu-
cose level. Before the symptom question-
naire, reaction time to auditory stimuli
was recorded during a standard vigilance
task (oddball paradigm) as a measure of
cognitive function. This task required the
patient to discriminate target pips (pitch:
1,200 Hz, duration: 60 ms, intensity: 64
dB SPL, probability  0.1) from ran-
domly interspersed frequent standard
pips of lower pitch (800 Hz) and to press
a button with the thumb of the dominant
hand as quickly as possible whenever he/
she recognized a target pip. Each task se-
quence contained 400 pips, presented
with interstimulus intervals randomly
varying between 1,000 and 3,000 ms.
Blood glucose concentration was
measured using the glucose dehydroge-
nase method (HemoCue B-Glucose-
Analyzer; A ¨ngelholm, Sweden). Serum
insulin, C-peptide, cortisol, and growth
hormone concentrations were measured
by commercial enzyme-linked immuno-
assays (all Immulite; DPC, Los Angeles,
CA).PlasmaACTHandglucagonconcen-
trations were also measured by immuno-
assays (ACTH: Immulite, DPC; glucagon:
Adaltis, Montreal, Canada). Plasma epi-
nephrine and norepinephrine were mea-
sured by standard high-performance
liquid chromatography with electro-
chemical detection (Chromosystems,
Munich, Germany). Data are reported as
means  SE. For statistical analyses, data
wereztransformedtoachievenormaldis-
Table 1—Clinical characteristics of the study population
Middle-aged
patients
Older
patients P
n 13 13
Sex (female/male) 6/7 5/8 0.69
Age (years) 51  27 0  1 0.001
Diabetes duration (years) 5  11 2  2 0.008
A1C (%) 7.4  4 7.4  2 0.97
BMI (kg/m
2) 27  12 7  1 1.00
Diabetes therapy
Diet alone 3 2 0.62
Metformin 7 9 0.42
Sulfonurea 2 3 0.62
Insulin 6 7 0.70
Insulin dose (units   kg
1   day
1) 0.20  0.07 0.26  0.07 0.92
Data are means  SE and prevalences. P values derive from 
2 or Student’s t test.
Table 2—Counterregulatory hormone levels at baseline and at the end of the hypoglycemic
clamp
Middle-aged
patients Older patients P
n 13 13
Epinephrine (pmol/l)
Baseline 233  62 191  47 0.59
Hypoglycemia 874  176 786  313 0.81
Norepinephrine (mol/l)
Baseline 2,177  324 2,021  206 0.69
Hypoglycemia 2,504  305 2,563  250 0.88
ACTH (pmol/l)
Baseline 4.99  0.890 4.57  0.643 0.70
Hypoglycemia 12.72  3.217 7.10  1.920 0.15
Cortisol (nmol/l)
Baseline 387  41 426  35 0.47
Hypoglycemia 548  58 476  44 0.33
Growth hormone (pmol/l)
Baseline 26.9  11.6 50.4  25.2 0.41
Hypoglycemia 250.4  59.5 245.6  135.7 0.98
Glucagon (pmol/l)
Baseline 49.9  9.3 38.2  4.1 0.26
Hypoglycemia 41.3  10.5 31.1  2.6 0.36
Data are means  SE. P values derive from Student’s t test.
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analysis was generally based on ANOVA,
including the repeated-measure factor
“hypo” for effects of hypoglycemia and
the between-subject factor “age” for the
older and middle-aged patient groups.
For pairwise comparisons, unpaired Stu-
dent’s t tests and 
2 tests were used. A P
value 0.05 was considered signiﬁcant.
RESULTS— Baseline blood glucose
levels did not differ between groups
(7.2  0.6 vs. 7.1  0.4 mmol/l; P 
0.83). The hypoglycemic plateau was
reached on average 39.2  5.7 min after
starting the insulin infusion in the mid-
dle-aged patients and 43.8  4.5 min af-
ter in the older patients (P  0.53).
During steady-state hypoglycemia, blood
glucose levels were comparable between
thetwogroups(2.70.03vs.2.80.02
mmol/l; P  0.71), as were levels during
the recovery period (P  0.25). There
werealsonogroupdifferencesinbaseline
concentrations of insulin (middle-aged
113  28 vs. older 304  209 pmol/l;
P  0.38) and C-peptide (middle-aged
0.620.07vs.older0.510.06nmol/l;
P  0.27). During the hypoglycemic
clamp, serum insulin levels were on aver-
age 2,159  160 pmol/l in the middle-
agedand1,812215pmol/lintheolder
patients (P  0.20). In response to hypo-
glycemia, serum C-peptide levels de-
creasedtocomparablenadirlevelsinboth
groups (0.27  0.02 vs. 0.28  0.04
nmol/l; P  0.76).
Levels of counterregulatory hor-
mones at baseline and at the end of the
hypoglycemic clamp are provided in Ta-
ble 2. ANOVA indicated a signiﬁcant in-
crease in epinephrine (P  0.002 for the
hypo main effect), norepinephrine (P 
0.001), ACTH (P  0.048), cortisol (P 
0.008),andgrowthhormone(P0.002)
during hypoglycemia, but there were no
difference in these increases between the
two patient groups (all P  0.18 for the
respective group 	 hypo interaction
terms). Glucagon levels did not signiﬁ-
cantly change during the clamp (P 
0.07) nor did they show any difference
between groups (P  0.57).
At baseline, scores of self-rated auto-
nomic(3.11.1vs.1.80.8;P0.36)
andneuroglycopenic(0.80.5vs.0.7
0.6; P  0.67) symptoms did not differ
between the middle-aged and older pa-
tients. Likewise, at the beginning of the
hypoglycemic plateau, symptom ratings
were comparable between middle-aged
andolderpatients(autonomicsymptoms,
3.2  1.4 vs. 1.9  0.9; P  0.42; neu-
roglycopenic symptoms, 2.0  1.2 vs.
1.5  1.0; P  0.61), remaining essen-
tially unchanged in comparison to base-
line scores (autonomic symptoms P 
0.82; neuroglycopenic symptoms P 
0.11, for both groups). However, at the
end of the hypoglycemic interval, scores
ofautonomicandneuroglycopenicsymp-
toms markedly increased in middle-aged
patients, whereas symptom scores in the
olderpatientsremainedalmostatbaseline
level (P  0.009 and P  0.007 for the
respective group 	 hypo interaction
terms) (Fig. 1). Also, at the end of the
hypoglycemic clamp, 7 of 13 middle-
aged patients, but only 1 of 13 older pa-
tients, correctly estimated their blood
glucose level to be 3.3 mmol/l (P 
0.011).
Olderpatientsoveralltendedtoshow
longer reaction time than middle-aged
patients (P  0.06 for the group main
effect) (Fig. 2). The prolongation of reac-
tion time induced by hypoglycemia (P 
0.001 for the hypo main effect) did not
differ between the two patient groups
(P  0.26 for the group 	 hypo interac-
tion term). Of note, reaction time re-
mained prolonged in both groups after
euglycemia had been reestablished for 30
min (57  19 ms in middle-aged and
82  23 in older patients vs. respective
baselinevalues;P0.012andP0.003,
respectively).
CONCLUSIONS — Our data indi-
cate that type 2 diabetic patients aged
65 years in contrast to middle-aged pa-
tients fail to perceive neuroglycopenic
and autonomic hypoglycemic symptoms
even in the presence of a comparable pro-
longation of reaction time induced by hy-
poglycemia. The age-related impairment
of hypoglycemia awareness was found
not to depend on alterations in neuroen-
Figure 1—Means  SE scores of self-rated autonomic (A) and neuroglycopenic (B) symptoms
duringthebaselineperiod,atthebeginningandendofthe30-minhypoglycemicplateau(indicated
bygrayshade),and30minafterrestorationofeuglycemiain13middle-aged(39–64years)( )
and 13 older (65 years) (f) diabetic patients. *P  0.05; **P  0.01.
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monal responses to hypoglycemia were
similar in both age-groups. Also, the
present study excludes a contribution of
thequalityofglycemiccontrolasreﬂected
by A1C levels and of diabetes medication
to hypoglycemia unawareness because
the two groups were comparable regard-
ing these variables.
The markedly longer diabetes dura-
tion in the older compared with the mid-
dle-aged group may have biased our
results and, in principle, may represent
the critical factor determining hypoglyce-
mia unawareness in older type 2 diabetic
patients. To clarify this issue, further
studies are necessary that should match
type 2 diabetic patients for disease dura-
tion rather than for age. Still, from the
clinicalpointofview,thisissueappearsof
minor relevance because age and disease
duration are highly correlated in the ma-
jority of older type 2 diabetic patients.
Theoretically, asymptomatic nocturnal
hypoglycemic episodes occurring in the
night before the experiment, which were
not systematically controlled for in our
study, could have inﬂuenced our results.
However, it appears rather unlikely that a
possibleemergenceofnocturnalhypogly-
cemia selectively affected one of the pa-
tient groups, both of which were
comparable regarding A1C levels and
medication.
The mechanisms underlying the se-
vere impairment of hypoglycemia aware-
ness in our older patients cannot be
derivedfromourdata.Giventhatthehor-
monal responses were pronounced and,
importantly, equally strong in both age-
groups, a mediation by neuroendocrine
counteregulatory failure as suggested by
previous studies (6) can be excluded.
Rather, it might be speculated that the
aged brain displays a diminished capabil-
ity of perceiving physiological and cogni-
tivealterationsduetohypoglycemia.This
assumption is buttressed by our ﬁnding
that older patients, while being com-
pletely unaware of the hypoglycemic
state, show a marked prolongation of re-
action time similar to that found in
middle-aged patients. In both groups, re-
action time was still prolonged 30 min
after restoration of euglycemia (i.e., when
self-rated symptoms in the middle-aged
group had already returned to baseline
levels). Considering that prolonged reac-
tion time may affect everyday life (e.g., by
increasing the risk of having accidents),
failure to perceive respective warning
symptomsduringhypoglycemiaisofhigh
relevance for patients, which underlines
the clinical implications of our ﬁndings,
although they probably cannot be gener-
alized to the effects of shorter hypoygly-
cemic episodes that may not elicit such
prolonged deteriorating effects on reac-
tion time. Also, reaction time is a single
aspect of cognitive function, which fur-
ther limits respective conclusions.
In summary, our results indicate dis-
tinct hypoglycemia unawareness in the
presence of pronounced hypoglycemia-
induced reaction time prolongation in
older type 2 diabetic patients. This ﬁnd-
ingmay,atleastinpart,explainwhyolder
patients are at a particularly high risk of
suffering from severe hypoglycemic epi-
sodes. Given that the risk of hypoglyce-
miaincreaseswiththeefﬁcacyofglycemic
control as reﬂected by low A1C levels
(1,3), our results strongly support the
view that glycemic targets for patients
should be deﬁned on an individual basis,
thus taking into account factors such as
age and probably also disease duration.
This strategy appears to be of particular
value considering that the recent results
of the ACCORD (Action to Control Car-
diovascular Risk in Diabetes) trial (10)
have massively challenged the traditional
“low-as-possible” dogma in diabetes care.
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